LabCorp's Credit Rating Bruised by Planned Genzyme Genetics Acquisition

Citing the $925 million cost of the proposed deal, the credit-rating firm said "the additional leverage, interest cost and potential integration issues related to an acquisition of this size make a near-term upgrade of the rating less likely."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.